FDA grants Moderna's mRNA-1893 fast-track eligibility for Zika virus vaccine
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The U.SFood andDrug(http://Administrationhttp://
(http:// has granted itsa fast-track qualification for the Zika virus vaccine mRNA-1893, thehttp://
company announcedNow, Moderna is conducting a Phase I clinicaltrial(http://to assess mRNA-1893 for Zika virus infection in adults inHealth (http:// About mRNA-1893
mRNA-1893 is a genetic vaccine that contains an mRNA sequence that encodes the structural protein of the Zika virus, designed to allow cells to secrete viral-like particles to simulate the response of cells after natural infection Preclinical studies published in the Journal of Infectious Diseases have shown that vaccination with mRNA-1893 during pregnancy in mice can prevent the spread of the Zika virus Currently, mRNA-1893 is evaluating safety, pharmacokinetics, and pharmacodynamics in healthy volunteers in a Phase I clinical study Moderna is advancing messenger RNA (mRNA) science to create a new and transformative drug for patients The role of mRNA drugs is to guide human cells to produce intracellular, intramembrane, or secreted proteins that have therapeutic or preventive effects and have the potential to solve a wide range of diseases
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
